GSK obtains positive CHMP opinion for Tafinlar and Tyverb
Tafinlar (dabrafenib) is recommended as treatment for adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Tyverb (lapatinib) is recommended as combination therapy with trastuzumab
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.